ABTI — Alterola Biotech Income Statement
0.000.00%
Last trade - 00:00- $0.29m
- $0.43m
Annual income statement for Alterola Biotech, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2020 September 30th | 2021 March 31st | 2022 March 31st | R2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 6 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-KT | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 0.33 | 0.309 | 6.47 | 2.05 | 2.4 |
| Operating Profit | -0.33 | -0.309 | -6.47 | -2.05 | -2.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.251 | -0.309 | -6.47 | -2.07 | -2.37 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.251 | -0.309 | -6.47 | -2.07 | -2.37 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.251 | -0.309 | -6.47 | -2.07 | -2.37 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.251 | -0.309 | -6.47 | -2.07 | -2.37 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.002 | -0.001 | -0.008 | -0.003 | -0.002 |
| Dividends per Share |